

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark G. Resnick

Serial No.: 09/663,218

Filed: September 15, 2000

For: METHODS FOR TREATING WOUNDS,
BURNS AND DERMATOLOGICAL
DAMAGE BY ADMINISTERING
SELEGILINE OR
DESMETHYLSELEGILINE

Group Art Unit: 1615

Examiner: L. Channavajjala

Atty. Dkt. No.: SOM700/4-9(A)8

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed after three months of the filing of the present application and after the receipt of a first Official Action on

the merits but before receipt of a Final Office Action UNDER 37 C.F.R. §1.113, or a Notice of Allowance under 37 C.F.R. §1.311. The fee as set forth in 37 C.F.R. § 1.17(p) for submission of a Supplemental Information Disclosure Statement is also enclosed. If the referenced check is inadvertently omitted or deficient, or should an overpayment be included herein, the Assistant Commissioner is authorized to appropriately deduct or credit the requisite amount from Vinson & Elkins L.L.P. deposit account No. 22-0365/SOM700/64001/4-9(A)8.

Respectfully submitted,



Margaret J. Sampson
Reg. No. 47,052
Attorney for Applicants

Vinson & Elkins L.L.P.
2300 First City Tower
1001 Fannin
Houston, Texas 77002-6760
512/495-8446

Date: January 22, 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark G. Resnick

Serial No.: 09/663,218

Filed: September 15, 2000

For: METHODS FOR TREATING WOUNDS,
BURNS AND DERMATOLOGICAL
DAMAGE BY ADMINISTERING
SELEGILINE OR
DESMETHYLSELEGILINE

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: SOM700/4-9A8

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

March 9, 2001
Date

Margaret J. Sampson
Margaret J. Sampson

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98(a)(3), a concise explanation of the relevance of the reference B4, WO 95/15160, is included because this reference is not in the English language. This reference refers to the use of selegiline and its derivatives in the preparation of a drug for the treatment of psoriasis.

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Vinson & Elkins L.L.P. Deposit Account No. 22-0365/SOM700/4-9A8.

Respectfully submitted,



Margaret J. Sampson
Reg. No. 47,052
Attorney for Applicant

Vinson & Elkins L.L.P.
2300 First City Tower
1001 Fannin
Houston, Texas 77002-6760
512/495-8446

Date: March 9, 2001

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
SOM700/4-9A8

SERIAL NO.
09/663,218

Resnick, Mark G.

FILING
September 15, 2000

GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,446,070	08-29-95	Mantelle	514	772.6	
	A2	5,387,615	02-07-95	Milgram et al.	514	654	
	A3	5,354,885	10-11-94	Milman et al.	560	43	
	A4	5,266,332	11-30-93	Dong et al.	424	473	
	A5	5,242,950	09-07-93	Fries Hastings	514	654	
	A6	5,221,536	06-22-93	Edgren et al.	424	473	
	A7	5,192,550	03-09-93	Edgren et al.	424	473	
	A8	5,190,763	03-02-93	Edgren et al.	424	473	
	A9	5,128,145	07-07-92	Edgren et al.	424	473	
	A10	5,057,321	10-15-91	Edgren et al.	424	413	
	A11	4,868,218	09-19-89	Buyske	514	646	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	WO 99/47133	09-23-99	PCT	A61K	31/135		
	B2	WO 97/33572	09-18-97	PCT	A61K	31/135		
	B3	WO 96/22068	07-25-96	PCT	A61K			
	B4	WO 95/15160	06-08-95	PCT	A61K	31/135		✓
	B5	0 593 807 A1	04-27-94	EPO	A61K	9/70		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Darr et al., Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage, British Journal of Dermatology 127: 247-253, 1992.
	C2	Granger et al., Superoxide Radicals in Feline Intestinal Ischemia, Gastroenterology, 81:22-29, 1981.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
SOM700/4-9A8

SERIAL NO.
09/663,218

Resnick, Mark G.

FILING
September 15, 2000

GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A12	4,861,800	08-29-89	Buyske	514	646	
	A13	4,826,875	05-02-89	Chiesi	514	534	
	A14	4,812,481	03-14-89	Reischig et al.	514	647	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B6	0 509 761 B1	09-11-96	EPO	A61K	31/135		
	B7	0 404 807 B1	06-30-93	EPO	A61K	31/135		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C3	Heinonen et al., Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites, Clin Pharmacol Ther, 56:742-749, 1994.
	C4	Heinonen et al., Pharmacokinetics and metabolism of selegiline, Acta Neurol Scand., 126:93-99, 1989.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

SERIAL NO. 09/663,218

FILING
September 15, 2000

GROUP	1615
-------	------

[illegible][illegible]

	C7	Knoll, The Striatal Dopamine Dependency of Life Span in Male Rats. Longevity Study with (-)Deprenyl, Mechanism of Ageing and Development, 46:237-262, 1988.
	C8	LaLonde et al., Antioxidants Prevent the Cellular Deficit Produced in Response to Burn Injury, J Burn Care Rehabil, 17:379-383, 1996.

DATE CONSIDERED

PAGE 4 OF 6

INFORMATION DISCLOSURE CITATION*(Use several sheets if necessary)*

Docket Number (Optional)

SOM700/4-9.18

Application Number

09/663,218

Applicant(s)

Resnick, Mark G.

Filing Date

September 15, 2000

Group Art Unit

1615***EXAMINER
INITIAL****OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)***C11****Schiller et al., Antioxidant therapy, Critical Care Medicine, 21(2):S92-S102, 1993.****C12****Stewart et al., Antioxidant Nutrients Protect Against UVB-Induced Oxidative Damage to DNA of Mouse Keratinocytes in Culture, J Invest Dermatol, 106:1086-1089, 1996.****EXAMINER****DATE CONSIDERED**

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.